Patents by Inventor Bruce Paul Randazzo

Bruce Paul Randazzo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of Melanoma Using HSV Mutant
    Publication number: 20120141418
    Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.
    Type: Application
    Filed: November 28, 2011
    Publication date: June 7, 2012
    Applicants: THE WISTAR INSTITUTE, Virttu Biologics Limited
    Inventors: Alasdair Roderick MacLean, Susanne Moira Brown, Nigel William Fraser, Bruce Paul Randazzo
  • Treatment of melanoma using HSV mutant
    Patent number: 8067012
    Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: November 29, 2011
    Assignees: Crusade Laboratories Limited, The Wistar Institute
    Inventors: Alasdair Roderick MacLean, Susanne Moira Brown, Nigel William Fraser, Bruce Paul Randazzo
  • Treatment of Cancer Using HSV Mutant
    Publication number: 20100172872
    Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.
    Type: Application
    Filed: January 22, 2010
    Publication date: July 8, 2010
    Applicants: CRUSADE LABORATORIES LIMITED, THE WISTAR INSTITUTE
    Inventors: Alasdair Roderick MacLean, Susanne Moira Brown, Nigel William Fraser, Bruce Paul Randazzo
  • Treatment of cancer using HSV mutant
    Patent number: 7674468
    Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.
    Type: Grant
    Filed: June 13, 2005
    Date of Patent: March 9, 2010
    Assignees: Crusade Laboratories Limited, The Wistar Institute
    Inventors: Alasdair Roderick MacLean, Susanne Moira Brown, Nigel William Fraser, Bruce Paul Randazzo
  • Combination therapy for type II diabetes or syndrome X
    Publication number: 20040167172
    Abstract: This invention provides methods of using a pharmacological combination of a biguanide agents, such as metformin, and one or more PTPase inhibiting agents and, optionally, one or more sulfonlylurea agents, including glyburide, glyburide, glipizide, glimepiride, chlorpropamide, tolbutamide, or tolazamide, for treatment in a mammal of Syndrome X, type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose levels in a mammal utilizing the combination of one or more PTPase inhibiting agents and one or more sulfonlylurea agents.
    Type: Application
    Filed: March 1, 2004
    Publication date: August 26, 2004
    Applicant: Wyeth
    Inventors: John Thomas Gwynne, Philippe John Robert Vitou, Bruce Paul Randazzo
  • Combination therapy for type II diabetes or Syndrome X
    Patent number: 6734197
    Abstract: This invention provides methods of using a pharmacological combination of a biguanide agents, such as metformin, and one or more PTPase inhibiting agents and, optionally, one or more sulfonlylurea agents, including glyburide, glyburide, glipizide, glimepiride, chlorpropamide, tolbutamide, or tolazamide, for treatment in a mammal of Syndrome X, type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose levels in a mammal utilizing the combination of one or more PTPase inhibiting agents and one or more sulfonlylurea agents.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: May 11, 2004
    Assignee: Wyeth
    Inventors: Bruce Paul Randazzo, Philippe John Robert Vitou, John Thomas Gwynne
  • Combination therapy for type II diabetes or Syndrome X
    Publication number: 20030018028
    Abstract: This invention provides methods of using a pharmacological combination of a biguanide agents, such as metformin, and one or more PTPase inhibiting agents and, optionally, one or more sulfonlylurea agents, including glyburide, glyburide, glipizide, glimepiride, chlorpropamide, tolbutamide, or tolazamide, for treatment in a mammal of Syndrome X, type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose levels in a mammal utilizing the combination of one or more PTPase inhibiting agents and one or more sulfonlylurea agents.
    Type: Application
    Filed: June 6, 2002
    Publication date: January 23, 2003
    Applicant: Wyeth
    Inventors: John Thomas Gwynne, Philippe John Robert Vitou, Bruce Paul Randazzo